Meeting NewsVideo

Polatuzumab vedotin plus obinutuzumab, lenalidomide shows promise in R/R follicular lymphoma

ORLANDO — Catherine Diefenbach, MD, director of the clinical lymphoma program and of hematology translational research, Perlmutter Cancer Center at NYU Langone Health, presented efficacy and safety data from a phase 1b/2 study of polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma at ASH Annual Meeting & Exposition.

These data showed that this novel triplet combination is a highly active, safe and tolerable regimen for patients with heavily pretreated relapsed and refractory follicular lymphoma, according to Diefenbach.

“We had a complete response rate that ranged from 62% to 73%,” she said. “For patients who were not refractory to their most recent line of therapy, the [complete response] rate was actually an astonishing 86%, but even for patients who were refractory to chemotherapy, their complete response rate was 40%, which is extremely impressive for this patient population.”

Disclosures: Diefenbach reports research funding from Bristol-Myers Squibb, Denovo, Genentech, Incyte, LAM Therapeutics, MEI, Merck, Millennium/Takeda, Seattle Genetics and Trillium, as well as consulting for Bristol-Myers Squibb, Genentech, Merck and Seattle Genetics.

ORLANDO — Catherine Diefenbach, MD, director of the clinical lymphoma program and of hematology translational research, Perlmutter Cancer Center at NYU Langone Health, presented efficacy and safety data from a phase 1b/2 study of polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma at ASH Annual Meeting & Exposition.

These data showed that this novel triplet combination is a highly active, safe and tolerable regimen for patients with heavily pretreated relapsed and refractory follicular lymphoma, according to Diefenbach.

“We had a complete response rate that ranged from 62% to 73%,” she said. “For patients who were not refractory to their most recent line of therapy, the [complete response] rate was actually an astonishing 86%, but even for patients who were refractory to chemotherapy, their complete response rate was 40%, which is extremely impressive for this patient population.”

Disclosures: Diefenbach reports research funding from Bristol-Myers Squibb, Denovo, Genentech, Incyte, LAM Therapeutics, MEI, Merck, Millennium/Takeda, Seattle Genetics and Trillium, as well as consulting for Bristol-Myers Squibb, Genentech, Merck and Seattle Genetics.

    See more from Discoveries from ASH: Lymphoma